Developmental status of synthetic immunomodulators.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000276:immunology; D000276:Adjuvants, Immunologic / Q000138:chemical synthesis; D000818:Animals; D001419:Bacteria / Q000276:immunology; D002473:Cell Wall / Q000276:immunology; D002927:Cimetidine / Q000494:pharmacology; D004050:Ditiocarb / Q000494:pharmacology; D006801:Humans; D007042:Hypoxanthines / Q000494:pharmacology; D007109:Immunity / Q000187:drug effects*; D007542:Inosine Pranobex / Q000494:pharmacology; D007978:Levamisole / Q000494:pharmacology; D010446:Peptide Fragments / Q000276:immunology; D016305:Thymopentin; D013946:Thymopoietins / Q000276:immunology; D014405:Tuftsin / Q000276:immunology
D000276:Adjuvants, Immunologic; D007042:Hypoxanthines; D010446:Peptide Fragments; D013946:Thymopoietins; D007978:Levamisole; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C026533:NPT 15392; D002927:Cimetidine; D004050:Ditiocarb; D016305:Thymopentin; D014405:Tuftsin; D007542:Inosine Pranobex